Optimizing the Immunogenicity of HIV Vaccines by Adjuvants - NIAID Workshop Report

Anjali Singh; César Boggiano; Michael A Eller; Milton Maciel Jr; Mary A Marovich; Vijay L Mehra; Annie X Mo; Kentner L Singleton; Wolfgang W Leitner

doi:10.1016/j.vaccine.2023.06.029

Optimizing the Immunogenicity of HIV Vaccines by Adjuvants - NIAID Workshop Report

Vaccine. 2023 Jul 12;41(31):4439-4446. doi: 10.1016/j.vaccine.2023.06.029. Epub 2023 Jun 16.

Authors

Anjali Singh¹, César Boggiano¹, Michael A Eller¹, Milton Maciel Jr¹, Mary A Marovich¹, Vijay L Mehra¹, Annie X Mo², Kentner L Singleton³, Wolfgang W Leitner⁴

Affiliations

¹ Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
² Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
³ Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
⁴ Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address: wleitner@niaid.nih.gov.

PMID: 37331838
DOI: 10.1016/j.vaccine.2023.06.029

Abstract

This report summarizes the highlights of a workshop convened by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), on April 4-5, 2022, to provide a discussion forum for sharing insights on the current status, key challenges, and next steps to advance the current landscape of promising adjuvants in preclinical and clinical human immunodeficiency virus (HIV) vaccine studies. A key goal was to solicit and share recommendations on scientific, regulatory, and operational guidelines for bridging the gaps in rational selection, access, and formulation of clinically relevant adjuvants for HIV vaccine candidates. The NIAID Vaccine Adjuvant Program working group remains committed to accentuate promising adjuvants and nurturing collaborations between adjuvant and HIV vaccine developers.

Keywords: Adjuvant; Broadly neutralizing antibody; HIV; Immunogenicity; Vaccine.

Publication types

Congress

MeSH terms

AIDS Vaccines*
Adjuvants, Immunologic
HIV Infections* / prevention & control
Humans
National Institute of Allergy and Infectious Diseases (U.S.)
National Institutes of Health (U.S.)
United States

Substances

Adjuvants, Immunologic
AIDS Vaccines